Back to Search
Start Over
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
- Publication Year :
- 2007
-
Abstract
- To assess the effect of age on response and compliance to treatment in patients with chronic myeloid leukemia (CML) we performed a sub-analysis within a phase II trial of the GIMEMA CML Working Party (CML/002/STI571). Since the WHO cut-off age to define an older patient is 65 years, among the 284 patients considered, we identified 226 (80%) younger patients (below 65 years) and 58 (20%) older patients (above 65 years) before starting imatinib. Response rates (hematologic and cytogenetic) were lower in the older age group but the probabilities of progression-free survival and overall survival (median observation time 3 years) were the same. Moreover, among complete cytogenetic responders, no differences were found in the level of molecular response between the two age groups. As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients.
- Subjects :
- Adult
Male
medicine.medical_specialty
Aging
Adolescent
Phases of clinical research
Antineoplastic Agents
Disease-Free Survival
Piperazines
Internal medicine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
hemic and lymphatic diseases
medicine
80 and over
Age Factors
Aged
Aged, 80 and over
Benzamides
Female
Humans
Imatinib Mesylate
Middle Aged
Pyrimidines
Treatment Outcome
Chronic
Adverse effect
Hematology
Leukemia
business.industry
Myeloid leukemia
Imatinib
chronic myeloid leukemia
imatinib
older age
medicine.disease
Surgery
Clinical trial
Imatinib mesylate
BCR-ABL Positive
business
medicine.drug
Myelogenous
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....e43363f028f1182a9a17b2f57dd4dfec